Table I.
Univariate analysis of the first therapeutic-target-achieving time and body mass index.
| Body mass indexa | |||||
|---|---|---|---|---|---|
| Group | Normal | Overweight | Degree I obesity | Degree II obesity | Mean initial dosage (mg)b |
| I | 30 (36.59) | 24 (26.67) | 14 (17.07) | 0 (0.00) | 3.59±0.92 |
| II | 18 (21.95) | 24 (26.67) | 20 (24.39) | 18 (37.50) | 3.10±0.29 |
| III | 28 (34.15) | 30 (33.33) | 36 (43.90) | 14 (29.17) | 2.66±0.23 |
| IV | 6 (7.32) | 12 (13.33) | 12 (14.63) | 16 (33.33) | 2.40±0.32 |
| χ2/F | 22.64 | 71 | |||
| P-value | <0.001c | <0.001d | |||
Among groups, P<0.05 was considered significant.
a
Data are presented as n (%).
b
Data are presented as the mean ± standard deviation.
c
P-value of the first therapeutic-target-achieving vs. normal, overweight, degree I and II obesity groups.
d
P-value of mean initial dose vs. normal, overweight, degree I and II obesity groups. The χ2 test was used to for the body mass index and the analysis of variance test for the mean initial dosage.